Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model

Henderson D.A. , Inglesby T.V. , Bartlett J.G. Smallpox as a biological weapon: medical and public health management. JAMA 1999; 281: 2127–2137.

Fenner F. , Henderson D.A. , Arita I. , Jezek Z. , Ladnyi I.D. Smallpox and its eradication. Geneva: World Health Organization, 1988.

National Institute of Allergy and Infectious Diseases. NIAID Category A, B & C Priority Pathogens. (Updated December 2009. Accessed December 2009.) Available from http://www.niaid.nih.gov/topics/biodefenserelated/biodefense/research/pages/cata.aspx.

National Institute of Allergy and Infectious Diseases. NIAID High Priority Biodefense Products. (Updated February 2010. Accessed September 2007.) Available from http://www.niaid.nih.gov/topics/biodefenserelated/biodefense/research/immunologybiodefense/Pages/default.aspx.

Meltzer M.I. , Damon I. , LeDuc J.W. , Millar J.D. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg Infect Dis 2001; 7: 959–969.

LeDuc J.W. , Jahrling P.B. Strengthening national preparedness for smallpox: an update. Emerg Infect Dis 2001; 7: 155–157.

O'Toole T. , Mair M. , Inglesby T.V. Shining light on ‘Dark Winter’. Clin Infect Dis 2002; 34: 972–983.

Huhn G.D. , Bauer A.M. , Yorita K. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis 2005; 41: 1742–1751.

Hammarlund E. , Lewis M.W. , Carter S.V. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med 2005; 11: 1005–1011.

Karem K.L. , Reynolds M. , Olson V. , Li Y. , Damon I.K. Monkeypox outbreak diagnostics and implications for vaccine protective effect. Nat Med 2006; 12: 495–496.

Reynolds M.G. , Yorita K.L. , Kuehnert M.J. Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis 2006; 194: 773–780.

Fulginiti V.A. , Papier A. , Lane J.M. , Neff J.M. , Henderson D.A. Smallpox vaccination: a review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin Infect Dis 2003; 37: 241–250.

Marriott K.A. , Parkinson C.V. , Morefield S.I. , Davenport R. , Nichols R. , Monath T. P. . Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 2008; 26: 581–588.

Fulginiti V.A. Risks of smallpox vaccination. JAMA 2003; 290: 1452.

Neff J.M. , Lane J.M. , Fulginiti V.A. Smallpox and smallpox vaccination. N Engl J Med 2003; 348: 1920–1925.

Cono J. , Casey C. , Bell D. , Centers for Disease Control and Prevention. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 2003; 52: 1–28.

Fulginiti V.A. , Papier A. , Lane J.M. , Neff J.M. , Henderson D.A. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 2003; 37: 251–271.

Wittek R. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis 2006; 10: 193–201.

Kawakami Y. , Tomimori Y. , Yumoto K. Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J Exp Med 2009; 206: 1219–1225.

Hopkins R.J. , Lane J.M. Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin Infect Dis 2004; 39: 819–826.

Kempe C.H. Studies on smallpox and complications of smallpox vaccination. Pediatrics 1960; 26: 176–189.

Kempe C.H. , Berge T.O. , England B. Hyperimmune vaccinial gamma globulin; source, evaluation, and use in prophylaxis and therapy. Pediatrics 1956; 18: 177–188.

Marennikova S.S. The use of hyperimmune antivaccinia gamma-globulin for the prevention and treatment of smallpox. Bull World Health Organ 1962; 27: 325–330.

Couzi G. , Kircher J. P. . Immunotherapie de la Variole. [Smallpox immunotherapy]. Bulletin de l'Institut d'hygiene du Maroc 1941; 1: 59–68. French.

Vaccinia Immune Globulin (human). Package insert 1991. Baxter Healtcare Corporation Deerfield, IL, USA.

Vaccinia Immune Globulin Intravenous (human; VIGIV). Package insert 2005. DynPort Corporation Frederick, MD, USA.

Vaccinia Immune Globulin Intravenous (human; VIGIV). Package insert 2005. Cangene Corporation Winnipeg, MB, Canada.

Shearer J.D. , Siemann L. , Gerkovich M. , House R.V. Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection. Antimicrob Agents Chemother 2005; 49: 2634–2641.

Goldsmith J.C. , Eller N. , Mikolajczyk M. , Manischewitz J. , Golding H. , Scott D.E. Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia. Vox Sang 2004; 86: 125–129.

Edghill-Smith Y. , Golding H. , Manischewitz J. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 2005; 11: 740–747.

Amanna I.J. , Slifka M.K. , Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev 2006; 211: 320–337.

Bell E. , Shamim M. , Whitbeck J.C. , Sfyroera G. , Lambris J.D. , Isaacs S.N. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 2004; 325: 425–431.

He Y. , Manischewitz J. , Meseda C.A. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine-induced immunity. J Infect Dis 2007; 196: 1026–1032.

Davies D.H. , Molina D.M. , Wrammert J. Proteomewide analysis of the serological response to vaccinia and smallpox. Proteomics 2007; 7: 1678–1686.

Davies D.H. , McCausland M.M. , Valdez C. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 2005; 79: 11724–11733.

Benhnia M.R. , McCausland M.M. , Su H-P . Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol 2008; 82: 3751–3768.

Lustig S. , Fogg C. , Whitbeck J.C. , Eisenberg R.J. , Cohen G.H. , Moss B. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J Virol 2005; 79: 13454–13462.

Benhnia M.R. , McCausland M.M. , Moyron J. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol 2009; 83: 1201–1215.

Benhnia M.R. , McCausland M.M. , Laudenslager J. Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J Virol 2009; 83: 12355–12367.

Tomizuka K. , Shinohara T. , Yoshida H. Double transchromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc Natl Acad Sci U S A 2000; 97: 722–727.

Benhnia M.R. , McCausland M.M. , Moyron J. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol 2009; 83: 1201–1215.

Newman F.K. , Frey S.E. , Blevins T.P. Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J Clin Microbiol 2003; 41: 3154–3157.

Benhnia M.R. , McCausland M.M. , Su H.P. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol 2008; 82: 3751–3768.

Lin C.L. , Chung C.S. , Heine H.G. , Chang W. Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J Virol 2000; 74: 3353–3365.

Moyron-Quiroz J.E. , McCausland M.M. , Kageyama R. , Sette A. , Crotty S. The smallpox vaccine induces an early neutralizing IgM response. Vaccine 2009; 28: 140–147.

Sakhatskyy P. , Wang S. , Chou T.H. , Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 2006; 355: 164–174.

Chen Z. , Earl P. , Americo J. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci USA 2006; 103: 1882–1887.

Chen Z. , Earl P. , Americo J. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol 2007; 81: 8989–8995.

Fogg C.N. , Americo J.L. , Earl P.L. Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge. J Virol 2008; 82: 8022–8029.

Nelson G. , Sisler J. , Chandran D. , Moss B. Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies. Virology 2008; 380: 394–401.